Patrick D Mitchell

Prof. Dr. Patrick D Mitchell

Medicine, Trinity College Dublin, Dublin, Ireland
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Chest
Verified
Journal Article
Closed access
PMPatrick D Mitchell
Patrick D Mitchell
POPaul M. O’bYrne
Paul M. O’bYrne

1 January 2017 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PMPatrick D Mitchell
Patrick D Mitchell
POPaul M. O'BYrne
Paul M. O'BYrne

28 January 2017 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
PMPatrick D Mitchell
Patrick D Mitchell
BSB. M. Salter
B. M. Salter
JOJohn Paul Oliveria
John Paul Oliveria
AEA. El‐Gammal
A. El‐Gammal
DTD. Tworek
D. Tworek
POP. M. O'BYrne
P. M. O'BYrne

14 January 2016 in Respiratory Research
Verified
Journal Article
Open access
PDF file
BSBrittany M. Salter
Brittany M. Salter
JOJohn Paul Oliveria
John Paul Oliveria
GNGraeme Nusca
Graeme Nusca
SSSteve G. Smith
Steve G. Smith
DTDamian Tworek
Damian Tworek
GGGail Gauvreau
Gail Gauvreau
The alarmin cytokines IL-25 and IL-33 are key promoters of type 2 inflammation. Basophils respond to alarmin cytokines, however the relationship of these cytokines with basophil activation and recruitment in human studies of allergic asthma has not been well characterized. This study investigated the effect of IL-25 and IL-33 on basophils in a model of allergic asthma. 10 mild allergic asthmatics underwent allergen and diluent inhalation challenges. Bone marrow aspirates were collected at pre-challenge and 24 h (h) post challenge. Peripheral blood and sputum samples were collected at pre-challenge, 7 h, and 24 h post-challenge to measure basophil expression of IL-17RB, ST2, and intracellular IL-25. Freshly isolated peripheral blood basophils from allergic donors were incubated overnight with IL-25 and IL-33, or sputum supernatant collected post-allergen to assess pro-inflammatory effects of mediators released in the airways. There were increased percentage of basophils expressing IL-17RB, ST2, and intracellular IL-25 collected from bone marrow, peripheral blood, and sputum after allergen inhalation challenge. In vitro stimulation with IL-25 and IL-33 increased the percentage of basophils expressing intracellular type 2 cytokines and surface activation markers, and primed eotaxin-induced migratory potential of basophils, which was mediated directly through IL-17RB and ST2, respectively. Stimulation of basophils with sputum supernatants collected post-allergen challenge up-regulated the percentage of basophils expressing markers of activation and intracellular type 2 cytokines, which was reversed following blockade of the common β chain (βc). Our findings indicate that the alarmin cytokines IL-33 and IL-25 increase basophil activation and migratory potential, and may pose as a novel therapeutic targets for the treatment of allergic asthma.

27 March 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AKAlan Glen Kaplan
Alan Glen Kaplan
PMPatrick D Mitchell
Patrick D Mitchell
ACAndrew J. Cave
Andrew J. Cave
RGRemi Gagnon
Remi Gagnon
VFVanessa Foran
Vanessa Foran
AEAnne K. Ellis
Anne K. Ellis
For years, standard asthma treatment has included short acting beta agonists (SABA), including as monotherapy in patients with mild asthma symptoms. In the Global Initiative for Asthma 2019 strategy for the management of asthma, the authors recommended a significant departure from the traditional treatments. Short acting beta agonists (SABAs) are no longer recommended as the preferred reliever for patients when they are symptomatic and should not be used at all as monotherapy because of significant safety concerns and poor outcomes. Instead, the more appropriate course is the use of a combined inhaled corticosteroid–fast acting beta agonist as a reliever. This paper discusses the issues associated with the use of SABA, the reasons that patients over-use SABA, difficulties that can be expected in overcoming SABA over-reliance in patients, and our evolving understanding of the use of “anti-inflammatory relievers” in our patients with asthma.

15 July 2016 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
AEAmani El-Gammal
Amani El-Gammal
JOJohn Paul Oliveria
John Paul Oliveria
KHKaren Howie
Karen Howie
RWRichard Watson
Richard Watson
PMPatrick D Mitchell
Patrick D Mitchell
POPaul M. O’BYrne
Paul M. O’BYrne
Rationale: Dendritic cells (DCs) are antigen-presenting cells essential for the initiation of T-cell responses. Allergen inhalation increases the number of airway DCs and the release of epithelial-derived cytokines, such as IL-33 and thymic stromal lymphopoietin (TSLP), that activate DCs. Objectives: To examine the effects of inhaled allergen on bone marrow production of DCs and their trafficking into the airways in subjects with allergic asthma, and to examine IL-33 and TSPL receptor expression on DCs. Methods: Bone marrow, peripheral blood, bronchoalveolar lavage (BAL), and bronchial biopsies were obtained before and after inhalation of diluent and allergen from subjects with asthma that develop allergen-induced dual responses. Classical DCs (cDCs) were cultured from bone marrow CD34+ cells. cDC1s, cDC2s, and plasmacytoid DCs were measured in bone marrow aspirates, peripheral blood, and BAL by flow cytometry, and cDCs were quantified in bronchial biopsies by immunofluorescence staining. Measurements and Main Results: Inhaled allergen increased the number of cDCs grown from bone marrow progenitors, and cDCs and plasmacytoid DCs in bone marrow aspirates 24 hours after allergen. Allergen also increased the expression of the TSLP receptor, but not the IL-33 receptor, on bone marrow DCs. Finally, inhaled allergen increased the percentage of cDC1s and cDC2s in BAL but only cDC2s in bronchial tissues. Conclusions: Inhaled allergen increases DCs in bone marrow and trafficking of DCs into the airway, which is associated with the development airway inflammation in subjects with allergic asthma. Inhaled allergen challenge also increases expression of TSLP, but not IL-33, receptors on bone marrow DCs.